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 Abstract 
Healthcare has changed significantly over the past few decades with the 
emergence of neoliberalism as a dominant ideology informing policy. This paper 
examines the Canadian Pain Coalition’s (CPC) conceptualization of chronic pain 
and its treatment in the context of neoliberalism. Through content analysis of the 
CPC’s online materials, we show how the advocacy group constructs pain as an 
individual’s responsibility and a physical disease that can be managed primarily 
with pharmaceutical medication.  Drawing on insights from the social 
determinants of health and feminist literatures, we suggest that the CPC’s 
construction of pain as a physical disease, an individual responsibility, and its 
emphasis on pharmaceutical treatment is inadequate in addressing the complex 
social, economic, and physical needs of people living with chronic pain.  Taking 
up Susan Markens’ concept of the “feminist paradox,” we suggest that there is a 
necessary tension in the construction of pain as disease.  On the one hand, it is 
constructed in terms of providing access to treatments, while on the other, it 
potentially medicalizes people living with chronic pain.  Finally, we discuss how 
the CPC does not adequately address the side of the tension concerning 
medicalization, given the strong association between the CPC and the 
pharmaceutical companies. 
 
Key words: neoliberalism, feminism, social determinants of health, chronic pain, 
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Introduction 
 Healthcare has changed significantly over the past few decades with the 
emergence of neoliberalism as a dominant ideology informing public policy. This 
perspective encourages a market approach to health, commodifying healthcare 
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and constructing patients as health “consumers” who freely choose which 
treatment or cure is most appropriate for their illness. In this context, people are 
represented as individual, autonomous actors, separated from their relationships to 
their work and social lives. The market-based approach to health in the context of 
neoliberalism conflicts with support for public social infrastructure and neglects 
the social determinants of health. The market-based approach promotes the 
privatization of aspects of health determinants, such as water, education, housing 
and waste, and unemployment protection (Armstrong and Armstrong, 1996). This 
approach also supports an increasing influence of the pharmaceutical industry in 
healthcare services as part of a broader trend towards public-private partnerships 
in the delivery of health services. Because neoliberal policies emphasize a market-
based and individualistic approach to health and healthcare, illness tends to be 
depoliticized and reduced to treatable diseases rather than to be seen as a public 
health problem influenced by a myriad social forces. 
 Through an examination of a Canadian-based patient advocacy group that 
receives funding from pharmaceutical companies, we seek to explore an 
organization’s conceptualization of chronic pain in the context of neoliberalism. 
According to results from the 2007/2008 Canadian Community Health Survey, 
about 1 in 10 Canadians aged 12 to 44 – 9% of males and 12% of females, an 
estimated 1.5 million people—experienced chronic pain.  The prevalence of 
chronic pain increased with age and was significantly higher among people in 
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households where the level of educational attainment was low and among the 
Aboriginal population (Ramage-Morin and Gilmour, 2010). This statistic 
demonstrates first, that chronic pain is a widespread problem in Canada, and 
second, that chronic pain affects people disproportionately according to their 
gender, race, and class. The feminist literature on chronic pain supports this 
contention that it is gendered, raced, and classed (e.g., Bendelow, 1993), but this 
fact has not translated into some of the most prominent advocacy work done on 
chronic pain, such as that of the Canadian Pain Coalition (CPC). We find this 
concerning given the history of women’s health issues being ignored or 
misrepresented and given that people living with chronic pain may be treated as a 
captive market for corporations that aim to make a profit from treating illness. 
This paper examines the online written content of the CPC’s website (including 
promotional and pain management materials). The CPC’s written materials 
suggest that pain is an individual responsibility and a physical disease that can be 
managed primarily with proper medication. The organization’s materials do not 
recognize the social determinants of pain, nor do they sufficiently address gender 
and chronic pain. Despite this omission, they receive significant funding from the 
pharmaceutical industry. We will address the complexity of these features of the 
CPC in relation to chronic pain with the use of feminist literature, and we will 
raise concerns about this form of patient advocacy. 
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Methods  
We conducted a content analysis of the Canadian Pain Coalition’s (CPC) 
website in 2010 (www.canadianpaincoalition.ca). We analyzed all available 
material on the CPC website during the months of September and October in 
2010, including “Home,” “About,” “Grants,” “Participate,” and all materials 
related to “National Pain Awareness Week.” We also analyzed materials posted 
on the website, including the CPC Charter (CPC, 2010, “The Charter”), and a 
booklet entitled “Conquering Pain for Canadians” (CPC, 2010, “Conquering Pain 
booklet”). 
Literature Review 
There is little sociological literature specifically dealing with chronic pain. 
We draw on literature from the Social Determinants of Health, critiques of 
medicalization, and feminist literature on gender and pain to argue that chronic 
pain cannot be understood solely as a physical phenomenon – that understanding 
the social factors causing chronic pain and influencing the experience of this 
condition are key to providing useful advocacy for those living with chronic pain. 
This literature challenges us to question how chronic pain has been constructed by 
the CPC, and what impact this construction can have on patients. 
Pain as Disease  
 Since the 1960s and 1970s, critical health scholars (e.g., Illich, 2002; Zola, 
1972) have written about the expansion of medicine’s control over the everyday 
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lives of people through the transformation of social conditions into medical 
problems.  A key critique within the medicalization literature is that the reduction 
of complex social, cultural, and environmental conditions to conditions of 
individual pathology effectively upholds medical authority and the pre-eminence 
of the biomedical model of disease.  A biomedical model of disease, which 
assumes a mechanistic body and an objective physical location of disease, is 
further challenged by phenomenological accounts of disease (Kleinman, 1988; 
Good, 1992; Good, 1994) and social constructionist approaches to illness (Lorber 
and Moore, 2002).  The assumption that all diseases should have objective 
physiological indicators renders conditions or symptoms that lack a physiogenic 
cause questionable. In order for pain to be understood and expressed within this 
biomedical model, the subjective experience of pain must be transformed into an 
objective medical problem (Good, 1992).  Kleinman (1988) and Good (1994) 
argue that a biomedical model which reduces illness to a physical condition or 
disease is not only inadequate in scope, but also focuses attention on the physical 
condition rather than on the person.   
 Furthermore, Lorber and Moore (2002) argue that illness is a social 
condition rather than a medical one; that is, while they do not deny the 
physiological changes that often accompany an illness, they argue that what 
constitutes illness or disease is not a physiological change or marker, but the 
inability to maintain social functioning. This social constructionist definition of 
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illness recognizes that social context and environment have as much to do with 
constituting illness and disease as does individual physiology or pathology.  
Feminist and critical scholars have also shown how medicalization is exercised in 
gendered, racialized, and classed ways (e.g. Lorber and Moore, 2002; Markens, 
1996).  Moreover, Bendelow (1993) has demonstrated how gendered assumptions 
regarding pain tolerance have resulted in women receiving inadequate treatment 
by physicians. This literature foregrounds the various social factors that shape 
conditions of health and illness.  
Social Determinants of Health and Chronic Pain 
 The Social Determinants of Health (SDH) literature has challenged the 
singularity of the biomedical model’s focus on the individual body.  Scholars 
writing in this field argue that a reductive biomedical model does not account for 
social factors that contribute to health inequalities and illness (Raphael, 2006; 
2008).  According to Raphael (2006), the term “social determinants of health” 
emerged as scholars sought to understand the mechanisms underlying the health 
disparities among different socioeconomic groups in a given population.  Social 
determinants of health refer to social and economic resources available to 
different groups including: income, food, housing, education, employment, and 
working conditions.  Despite the abundant evidence that decreasing disparity 
among socioeconomic groups improves health for the population, Raphael (2006) 
argues that health policy makers in Canada have been slow to address these 
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societal factors.  He suggests that this reticence by policy makers is related to the 
individualist approach of public health strategies which are based on biomedical 
and epidemiological traditions that conflict with a structural approach to 
understanding health and its determinants.   
 To date, there is little SDH research that focuses specifically on chronic 
pain.  One exception is Goldberg and McGee’s (2011) insightful work in which 
they make important links between chronic pain and social determinants of health 
such as employment, socioeconomic status, neighbourhood, and education.  
Drawing on broader SDH literature, the authors argue that the severity and 
frequency of chronic pain are more pronounced for disadvantaged or marginalized 
groups.  Rather than viewing chronic pain solely from a biomedical model, the 
authors argue for addressing the social factors that contribute to this condition.  
They suggest that without broader social policies that address things such as 
proper nutrition, secure employment, and safe housing, the needs of people living 
with chronic pain will continue to go unaddressed.  While the field very usefully 
points to the social factors affecting health, it is often uncritical of the way in 
which diseases come to be constructed as a medical issue. While the SDH 
literature can be useful in arguing that there should be better recognition of health 
problems and better access to health services based on social location, other 
critical scholarship has investigated the implications of labeling conditions 
‘diseases’ and thus bringing them under medical expertise.  
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The Feminist Paradox 
 Feminist health scholars have explored the advantages and disadvantages 
of having a condition named as a disease and thus medicalized. This work is 
helpful in critically addressing the CPC’s construction of chronic pain. Susan 
Markens (1996) introduces the idea of the “feminist paradox” in her analysis of 
the medicalization of premenstrual syndrome.  She writes:  
“That accounts of women’s experiences of PMS figure prominently in the 
rhetorical legitimation of PMS as a medical phenomenon poses a 
challenge to feminists because they critique the lack of attention to 
women’s health problems by the medical establishment and are, at the 
same time, skeptical of how women and the female body are understood 
and described when the complaints of women are taken seriously. It is this 
paradox that causes conflict among feminists” (p. 43).    
 
We suggest that both sides of this feminist paradox must be considered 
when examining the work of the CPC and it’s scholarship on chronic pain.  On 
the one hand, feminists writing on chronic conditions with parallels to chronic 
pain argue for a biomedical diagnosis for chronic conditions in order to have 
women’s pain legitimated.  Similarly then, we suggest that the construction of 
chronic pain as disease provides women and marginalized others living with pain, 
access to medical attention and treatment.   
 While there is no specific feminist work on chronic pain, feminists have 
examined conditions such as chronic fatigue syndrome (CFS), fibromyalgia 
(FMS), and endometriosis.  While endometriosis is a condition diagnosed in 
biological females, CFS and FMS are highly gendered conditions in which 
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women receive diagnoses in greater number than men.  All three conditions also 
have chronic pain as a key symptom.  Much of the feminist work on these 
conditions emphasize the need for women’s accounts of chronic pain to be taken 
seriously by physicians and the biomedical legitimacy of their pain accounts. 
Feminist theorists have noted that women have often had their pain symptoms 
under-recognized, dismissed, or posed as ‘natural.’ Women have had the 
credibility and legitimacy of their self-reports of pain and discomfort questioned 
in the case of conditions such as fibromyalgia (Werner and Malterud, 2003), 
chronic fatigue syndrome (Asbring and Narvanen, 2002), undefined forms of pain 
(Johansson et al., 1999), and endometriosis (Denny, 2009). Many feminist 
scholars writing in response to the dismissal of women’s subjective reports of 
physical pain have foregrounded women’s experiences and have shown the 
effects of their dismissal on women and their health. Caplan (2001) and Cahn 
(2003) provide first-hand accounts of living with CFS, thus challenging those, 
including other feminists, who argue that CFS is solely a psychogenic condition 
and not a physical one. Cahn (2003) describes how lack of acknowledgement of 
CFS as a physical disease led others to identify her as “mentally ill” and Caplan 
(2001) experienced judgment and alienation by co-workers and friends. In some 
cases, because many physicians assume that CFS or FMS are psychogenic 
conditions, the therapeutic treatment that women receive is limited to 
psychotropic drugs (Caplan, 2001).  
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Many feminist scholars also emphasize how obtaining a medical diagnosis 
enables women to access treatment and services that were previously denied. For 
example, White, Lemkau and Clasen (2001) recognize the ambiguity of the 
diagnostic criteria for FMS; however, they argue for its application because the 
medical legitimacy granted by a diagnosis improves access to medical treatment 
and insurance benefits for women. Crooks, Chouinard and Wilton (2008) show 
that women actively negotiate an FMS diagnosis and identity in order to access 
ODSP, disability insurance in Ontario, Canada. An FMS diagnosis establishes the 
woman as “disabled enough” and entitles her to state benefits linked to 
recognition of her inability to maintain paid employment. Conversely, without 
this diagnosis, women lack the basis on which to make claims on the state and 
thus are not eligible for benefits based on their physical pain.  While this body of 
feminist literature is effective in arguing for the need for the medical community 
to take women’s accounts of chronic conditions and pain seriously, it neglects to 
provide a critique of medicalization or of the marketing of treatments for 
women’s illnesses. 
 Broader feminist critiques in health argue against medicalization, 
overmedication, and the erasure of subjective experiences of illness.  Applying 
the other side of the feminist paradox to chronic pain we suggest that when 
gender, race, class and ability are ignored, the experiences of pain are falsely 
universalized and treatment approaches can be reductive and inappropriately 
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simplified.  In the context of neoliberalism and the political clout of large 
pharmaceutical companies, universalized treatment often means prescription 
drugs.   
 Feminist scholars critical of medicalization argue that women’s health and 
bodies have been objectified and pathologized by the medical establishment. This 
has not necessarily resulted in better health for all women.  Moreover, they argue 
that medical technologies have been used to control and govern women and their 
bodies.  There is an extensive and troubled history of pharmaceutical remedies for 
women’s health issues. The pharmaceutical industry has also profited greatly 
from defining conditions, such as PMS and menopause, as diseases that need to 
be cured with pharmaceutical remedies.  While in some cases pharmaceutical 
solutions for women’s health conditions have been helpful, in many cases they 
have had contradictory repercussions. For instance, while the contraceptive pill 
has been welcomed by many women as an effective and even liberating method 
of birth control, it’s early and even some recent compositions such as Yasmin and 
Yaz have had serious adverse side-effects for some women (Johnson, 2011).   
Analysis 
 The CPC was formed in May 2002 as a partnership of eight patient groups 
and individual patients. It is associated with the Canadian Pain Society – a 900-
member professional organization of clinicians and researchers.  According to its 
website, its mission is to “promote sustained change and improvement in pain 
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management in Canada,” (CPC, 2010, “About Pain Awareness Week”) and its 
primary goal is to have the public and professionals recognize chronic pain as a 
disease in order to increase funding for research on pain, specifically on new 
treatments for intractable or chronic pain (CPC, 2010). The CPC Charter states, 
“pain in Canada is an epidemic” (CPC, 2010, “The Charter”) and that patients are; 
entitled to have their reports of pain taken seriously, receive compassionate and 
sympathetic care, have treatment/care, follow-up, and periodic reassessment, 
actively participate, or have their parents or caregivers participate in their 
treatment plan development, gain timely access to best-practice care, and gain 
adequate information in order to consent to their treatment (ibid). While these 
entitlements do not necessarily seem to be at odds with those argued for by 
critical social scientists, a closer examination of how they construct chronic pain 
and the types of treatment they recommend suggest that the CPC’s 
conceptualization of pain is reductively physical with an emphasis on 
pharmaceutical treatment.   
 The CPC offers information and education on its website in the form of a 
booklet titled, “Conquering Pain for Canadians” (CPC, 2010, “Conquering Pain 
booklet”).  This booklet is made up of seven topics, each posed as a question. 
Three of the seven topics deal with healthcare professionals and/or medication.  
The question, “How should I talk to healthcare professionals about pain?” 
instructs patients not to ignore their pain, but to establish a “partnership” with a 
HEALTH TOMORROW, VOL. 1(2013).  
39 
 
healthcare professional.  They establish that a physician is the first person to 
approach regarding pain management and they suggest describing pain according 
to single word adjectives such as “throbbing, stabbing, burning” and an intensity 
scale ranging from 0-10 (CPC, 2010, “How should I talk to healthcare 
professionals?”).  The question, “Are there things I can do besides taking 
medication that can help my pain?” is itself phrased with the assumption that 
medication is the first response to pain. In their response to this question, the CPC 
writes that pain is best managed when medication is combined with non-
pharmacological options such as “massage, heat, cold, and topical analgesic 
creams.” Not only are these non-pharmacological options solely focused on the 
individual body, but the CPC is advocating for alternative treatments in addition 
to, not instead of, medication (CPC, 2010, “Are there things I can do?”). Lastly, in 
answer to “What about pain medications?” there is a clear emphasis on taking 
medication for pain.  They write that a patient should not wait until the pain is 
“really bad” before taking medication, because “pain medications are an 
important part of treating your pain” and “it is important to treat your pain as 
early as possible.”  They write that pharmaceutical medication can be used for 
mild to severe forms of pain. In other words, medication is not the last, but the 
first line of treatment for all pain. For those concerned about addiction, the 
website claims not only that addiction to opioids used to treat chronic pain is 
uncommon, but that, “A physical dependence on opioids for pain relief is not 
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addiction.”  This is perhaps the most compelling ‘push’ towards medication. Until 
very recently, in order to allay widely held concerns regarding addiction to pain 
medications, the CPC has defined addiction so that physical dependence on 
opioids no longer signals addiction (CPC, 2010, “What about pain 
medications?”). 
 The remaining three questions are not focused on medications. They 
outline how pain can affect a person’s mental wellbeing, sleep patterns, 
relationships, ability to work, posture, mobility, and lifestyle choices. The CPC’s 
description of how pain can influence a person’s life is very individualized, and 
emphasizes ‘lifestyle’ as a personal choice. In answer to the question “What are 
the Effects of Pain on my body? Can I do anything myself?” the CPC suggests an 
exercise routine such as swimming or yoga. There is no mention of the kind of 
work a person does and whether this might be contributing to chronic pain, the 
person’s role as a caregiver, the person’s access to an exercise facility, or even to 
basic health services (CPC, 2010, “What are the effects?”). In answer to, “Is there 
a connection between pain and stress and depression? What can I do myself to 
lower stress?” the CPC tells the patient to sit in a quiet room and take deep 
breaths, then think of what colour the pain is and see how “the colour shrinks 
down to a smaller size as you breathe in and out” (CPC, 2010, “Is there a 
connection?”). In answer to, “How can I have good sleep hygiene” the CPC 
suggests using extra pillows, avoiding caffeine before bed, and only going to bed 
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when sleepy (CPC, 2010, “Sleep hygiene?”).  The options proposed as additions 
to medication are personal lifestyle choices aimed at the individual level; they do 
not consider how broader social or institutional contexts such as employment or 
extended health benefits might impact their ability to manage living with chronic 
pain.   
  In the “Conquering Pain for Canadians” booklet, the CPC defines chronic 
pain as “pain that persists over three months, beyond when an injury should have 
healed. Chronic pain can be intermittent (occurs in a pattern) or persistent (lasting 
more than 12 hours daily) and can be considered as disease itself.” (CPC, 2010, 
“Is all pain the same?”). To further distinguish between acute and chronic pain, 
the booklet continues: “It is important to understand that chronic pain is not just a 
continuation of acute pain. Unlike acute pain, which alerts your body to injury, 
chronic pain serves no purpose” (CPC, 2010, “Is all pain the same?”). 
Constructing chronic pain as disease involves producing a new category of pain 
and differentiating between acute and chronic pain. Thus, while acute pain serves 
as the symptom or sign of some other underlying cause of pain, chronic pain does 
not. The construction of chronic pain as disease is a shift from understanding pain 
as primarily a symptom of another underlying cause or disease. The definitions of 
acute and chronic pain offered by the CPC and its construction of chronic pain as 
disease fit squarely within a biomedical model. 
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While the CPC draws on the language of population health by describing 
pain as an epidemic, their website offers no further discussion of the broader 
social determinants of health that may contribute to developing chronic pain and 
the experiences of living with it.  The absence of a larger structural view of 
chronic pain limits the political scope of the CPC and neglects to acknowledge 
socioeconomic and other differences among people living with chronic pain. The 
organization emphasizes individualized solutions to chronic pain and prioritizes 
medications; this is an approach that complements the industry that stands to 
profit from medicating chronic pain, but does not address the causes of chronic 
pain or fully address the complex needs of people living with chronic pain.   
According to the CPC’s website, both FMS and CFS are conditions that 
are included under the larger umbrella of chronic pain and thus, in some respects, 
this can be considered a move to reduce some of the ambiguity associated with 
these conditions. As a patient advocacy group and an organization aimed at 
increasing public awareness of chronic pain, their move towards stabilizing 
chronic pain as disease may be viewed as an effort to legitimize chronic pain and 
to take seriously the experiences of people living with chronic pain. The emphasis 
on chronic pain as disease and the recognition of the physical basis of chronic 
pain conditions (e.g., Richman and Jason, 2001) seems to fit with one side of the 
feminist paradox that argues for medical attention to chronic pain. It is easy to see 
how the label of “disease” can be important for those living with chronic pain and 
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struggling to have their experiences recognized and may provide access to 
treatment and services. On the other hand, however, the construction of chronic 
pain as a disease itself and not a symptom of a disease or syndrome raises 
concerns regarding medicalization and the efforts of pharmaceutical companies in 
producing a market for their drugs.  This side of the feminist paradox has received 
less attention in the feminist literature on conditions associated with chronic pain 
and is completely absent in the work of the CPC.  
Discussion 
 The CPC welcomes memberships from corporations including 
pharmaceutical companies within Canada, for a fee of $500.00 (CPC, 2010, 
“Membership”). Pfizer seems to be closely associated with this coalition in 
several ways: the CPC Healthcasts present discussions on key topics related to 
neuropathic pain, and are funded through an unrestricted educational grant from 
Pfizer Canada (CPC, 2010, “Healthcasts”); the CPC’s Pain Resource Centre, a 
resource about pain and pain management for Canadians is sponsored by Pfizer 
Canada (CPC, 2010, Pain Resource Centre, “Sponsors of this Site”); several 
members of the CPC’s Board of Directors have a relationship to Pfizer, as 
researchers who are receiving funding from Pfizer, as a member of a Pfizer 
awards committee, or in one person’s case, as Pfizer’s National spokesperson for 
Fibromyalgia (CPC, 2010, “Board of Directors”).  The CPC recently 
commissioned “The Report on Pain” exploring “the patient journey of Canadians 
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living with chronic pain” with support from Pfizer Canada Inc. (CPC, 2011, 
“Report on Pain”).  Pharmaceutical corporations such as Pfizer have a vested 
interest in what they call “Community Investments.” An investment entails some 
sort of profitable return. Pfizer is a leading pharmaceutical company that markets 
dozens of pain medications, some requiring long-term use which means 
substantial profits. As the CPC claims on its website, chronic pain is Canada’s 
“silent epidemic” affecting approximately 6 million people. For Pfizer, instilling 
Canadians with a sense of entitlement to pain treatment and narrowly defining 
treatment as long-term pharmaceutical use is an intelligent business move.  If, as 
reflected in the CPC website, chronic pain is a disease, pain medication the 
primary means of treatment for all levels of pain, and physical dependency not 
addiction but long-term pain management, then this supports the production of a 
large market for pharmaceutical drugs.   
 The close association between coalitions such as the CPC and the 
pharmaceutical industry is a growing phenomenon linked to the increasing 
influence of the pharmaceutical industry in healthcare in a context of 
neoliberalism. This profit-driven industry dedicates considerable resources to 
marketing in direct and indirect ways. Direct-to-consumer advertising is one way 
that the industry directly promotes drugs to consumers. In a more indirect fashion, 
pharmaceutical companies sponsor medical research and analyses that are 
developed to influence the opinions of researchers and practitioners about the 
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efficacy of their drugs (Sismondo, 2009) and outsource medical writing to 
agencies that produce favourable medical reporting on drugs (Healy, 2004). 
Sponsoring patient advocacy groups with a proclivity for recommending 
treatment in the form of pharmaceutical drugs could be considered yet another 
form of marketing. The CPC represents an apparent mobilization of patients to 
demand recognition of pain in particularly biomedical terms.   
 A number of social scientists have critically examined the relationship 
between the pharmaceutical industry and patient advocacy groups (Batt, 2005; 
2010; Jones, 2008; Ball, 2006; Marshall, 2006; Toiviainen et al., 2004; Tuffs, 
2006; Perehudoff and Alves, 2011). In a recent exploration of the debate over 
partnerships between patients’ groups and pharmaceutical companies in Canada, 
Batt (2010) argues that “pharmaceutical companies are problematic funding 
sources for [patient groups] because they often have a direct interest in the 
outcome of the group’s advocacy, which in turn can cloud the judgment of 
decision makers within the organization” (p. 72).  
 Some argue that organizations that accept industry funding seem to spend 
their efforts pressing for access to the newest and best drugs on the market, rather 
than asking ‘tough’ questions about the safety and efficacy of these drugs (Batt, 
2010; Mintzes, 2007). This concern is particularly pressing with reports of over 
prescription of drugs such as OxyContin, Purdue Pharma’s formulation of 
oxycodone. A study by Gomes et al. (2011) found that prescriptions for opioid 
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analgesics have risen by 16.2 per cent between 2003 and 2008. Among patients 
for whom high or very high doses of opioids were dispensed in 2004, 19.3 per 
cent of deaths during the subsequent 2 years were opioid-related (Gomes et al., 
2011). According to Ontario's Health Ministry, between 300 and 400 people die 
each year in the province from opioid-related overdoses and that the opioid most 
frequently found during autopsies in recent years is oxycodone (Kirkey, 2012). 
Purdue Pharma is now phasing out OxyContin and replacing it with OxyNEO, 
which is apparently more difficult to crush or liquefy, for snorting or injection 
purposes (ibid). Six provinces have already said they will restrict access to the 
new formation (ibid).  As we discussed above, until the recent media attention 
paid to OxyContin addiction, the CPC website emphasized the safety of opioids 
and made no mention of studies that suggest otherwise. According to a February 
21, 2012 new release, members of the Canadian Pain Society have participated in 
the National Dialogue on Prescription Drug Misuse, sponsored by the Canadian 
Centre on Substance Abuse, “to develop strategies that can reduce the harms of 
prescription pain medication misuse in a way that does not harm people with pain 
who require these medications as an essential part of their treatment.” In the 
release, the Canadian Pain Society states: “We cannot let people with serious pain 
become the collateral damage of the war on prescription drug misuse.” At the 
same time, in the context of the discussion of provincial restrictions for OxyNEO, 
Dr. Roman Jovey, a past president of the Canadian Pain Society said “Putting any 
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medication on exceptional access creates a huge barrier to its use because of the 
paperwork and ‘hassle factor’ involved for doctors.” (ibid). While spokespersons 
for the Canadian Pain Society have stepped up to condemn misuse of opioids, 
they continue to stress access to pain medications for their patients. 
A recent study of 22 patient and consumer organizations, and 
pharmaceutical funding by Perehudoff and Alves (2011) from Health Action 
International Europe, found that “a financial relationship between commercial and 
civil society groups could jeopardize the uniqueness of the patient and consumer 
perspective and threaten the integrity of the multi-stakeholder format and the 
policy formulation process” (p. 5).  Both Jones (2008) and Batt (2005) 
acknowledge that health consumer groups or ‘patient groups’ are often motivated 
by the intention of representing the voices of their constituents as part of a social 
movement for patients’ rights. Patient groups find themselves in a situation where 
they do not have the funding to do their work effectively and must rely on 
industry for financial support. Disease and consumer groups have played an 
increasingly powerful role in health policy since the 1990s (Batt, 2005). 
Governments have cut back on support for community-based advocacy over the 
past two decades, leading advocacy groups to seek funding elsewhere, and the 
pharmaceutical industry is all too eager to provide this support. Partnerships 
between non-profit groups and the private sector are a funding strategy that has 
emerged from the 1990s climate of deficit-reduction and privatization (Batt, 
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2010).  Governments in the UK, Canada, the US, and elsewhere have facilitated 
this trend by supporting “partnership” projects between advocacy groups and the 
private sector.  
 The relationship between patient advocacy groups and the pharmaceutical 
industry is complex, and we do not argue that there is a simple uni-directional 
relationship of power that moves from industry to patient groups (e.g., Novas, 
2007 and Werner et al., 2004).  What is concerning, however, is that these patient-
led movements that advocate for medical attention for conditions such as chronic 
pain may be unduly influenced by pharmaceutical companies that are driven by a 
fiduciary responsibility to their shareholders to increase profits. We suggest that 
this influence may be reflected in what we suggest is the indirect marketing of 
medication as the primary means of treating chronic pain. The effectiveness of 
this marketing is achieved by the erasure of the paradox and complexities of 
chronic pain from a condition that is at once physical, social, and psychological, 
to one that is solely physical. The CPC’s website demonstrates how their 
rendering of chronic illness supports a particular perspective on health and 
medicine which does not explicitly endorse a corporation or drug, but does 
support an ideological and political model of health that is consistent with a 
neoliberal approach to health. When we consider the history of the pharmaceutical 
industry’s efforts to market drugs and technologies to women, a feminist analysis 
of the CPC seems imperative.  
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Conclusion 
 We suggest that in the context of neoliberalism, advocacy groups have 
come to play an important role in drawing attention to specific health conditions.  
In the case of chronic pain, the CPC’s online materials appear to reduce chronic 
pain to a biomedical disease and to emphasize pharmaceutical treatment as the 
most effective and long-term method of treatment.  We suggest that this does not 
address the concerns of critical social scientists discussed above. While the 
attention that the CPC brings to the condition of chronic pain appears to address 
feminist arguments for increased medical attention to conditions of chronic pain, 
its erasure of the specificities of people’s lives, absence of broader social 
structural concerns, and a lack of critique of the pharmaceutical industry does not 
address concerns raised by the SDH and feminist literatures. We suggest that the 
feminist paradox can be productive within critical analyses of health movements 
and advocacy groups. While the work of the CPC is effective in bringing 
legitimacy to the physical experience of pain, its lack of engagement with 
concerns related to medicalization and its emphasis on pharmaceutical medication 
is problematic. That is, while it is effective in addressing one side of the feminist 
paradox it does not address the other side, the critique of the medicalization and 
corporatization of health issues. In order to more fully address the complex health 
needs of gendered, classed, and racialized people, both sides of the paradox must 
be considered. 
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